cancerous activity News
-
Filtricine Preclinical Results Published
Filtricine is pleased to announce that the preclinical research results of its proprietary medical food technology, Targeted Nutrients Deprivation (TND), have been published in Nutrition and Cancer. “Broad Anti-Cancer Activity Produced by Targeted Nutrients Deprivation (TND) of Multiple Non-Essential Amino Acids” Filtricine’s core medical food technology is the ...
-
Akrotome has been awarded $1.77M by The National Cancer Institute
Akrotome receives grant for the commercialization of a topical probe for margin determination in skin cancers Akrotome Imaging has received a $1.77M SBIR Phase II grant to assist in the clinical translation of its FIRE™ probe for margin assessment in skin cancer. In this application, FIRE is applied ex-vivo to skin tissue that has been surgically removed. When the probe detects cancer, ...
-
Lixte Biotechnology Announces Filing of First Patent Application Resulting from Collaboration with the Netherlands Cancer Institute and the Oncode Institute to Identify the Most Promising Drug Combinations for Lead Clinical Compound, LB-100
Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) reported that its the recent collaboration with the Netherlands Cancer Institute (NKI), Amsterdam, one of the world’s leading comprehensive cancer centers, and Stichting Oncode Institute (Oncode Institute), Utrecht, a major independent cancer research center, has led to an initial joint patent application covering LB-100 combination therapy ...
-
Vitanova Biomedical and LiteCure Medical Lasers Announce Global Strategic Partnership
Vitanova Biomedical, the San Antonio, Texas-based biotechnology company dedicated to improving the lives of cancer patients and the healthcare professionals who care for them, has entered a global strategic partnership with LiteCure Medical Lasers. Vitanova’s light-activated targeted cancer drug offers a cost effective and efficacious cancer therapy with the potential to eliminate unwanted ...
-
LIXTE Biotechnology Holdings to Present at Planet MicroCap Showcase: VIRTUAL 2022 Investor Conference
LIXTE Biotechnology Holdings, Inc. (Nasdaq:LIXT) today announced it will be presenting at the Planet MicroCap Showcase: VIRTUAL 2022 investor conference Wednesday, December 7, 2022 at 3:30 p.m. EST/12:30 p.m. PST. John S. Kovach, M.D., founder and CEO of LIXTE, will host the presentation. Dr. Kovach, with his team, will be answering questions at the conclusion. To access the presentation, ...
-
LIXTE Biotechnology Announces the Closing of $5.8 Million Registered Direct Offering Priced At-The-Market
LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, today announced that it has closed a registered direct offering with certain institutional and accredited investors for $5.8 million of common stock. The Company issued a total of 2,900,000 shares of common stock at a purchase price of ...
-
LIXTE Biotechnology Announces Preclinical Results of its Collaboration with the Netherlands Cancer Institute, Revealing Striking Anti-Cancer Activity of LB-100 In Novel Drug Combinations
LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage pharmaceutical company focused on developing and commercializing cancer therapies, announces that Professor René Bernards, Netherlands Cancer Institute (NKI), Amsterdam, presented new data from promising drug combinations of LIXTE’s lead clinical cancer compound, LB-100, at the Annual Meeting of American Association ...
-
Vitanova Biomedical Awarded Competitive Grant from the National Science Foundation
Vitanova Biomedical (VNB), the San Antonio, Texas-based biotechnology company dedicated to improving the lives of cancer patients and the healthcare professionals who care for them, has been awarded a National Science Foundation (NSF) SBIR grant for $225,000 to conduct research and development (R&D) work on the company’s light-activated intracellular acidosis (LAIA) targeted cancer ...
-
CD BioGlyco Announced Service for Analysis of Glycolytic Enzymes in Cancer Cells
CD BioGlyco, a biotechnology company that provides multi-omics analysis of cancer cell glycolysis including genomics, proteomics, metabolomics and metabolic fluxomics, now offers analysis of glycolytic enzymes in cancer cells, enabling thorough understanding of cancer cell glycolysis pathways. The capacity of cancer cells for aerobic glycolysis is 20–30 times greater than that of normal ...
By CD BioGlyco.
-
American cancer society corporate initiative -- call for nominations: 2010 corporate impact awards series
The American Cancer Society Corporate Initiative program has opened its nomination process for the 2010 Corporate Impact Awards Series, which will honor companies for their engagement in targeted efforts to significantly impact cancer"s effect in the workplace; to contribute funds to the American Cancer Society to fight the disease; and to address responsible community involvement - all in ...
-
Lixte Biotechnology Holdings, Inc. Announces that enrollment has resumed in national cancer institute’s trial to determine ability of Lixte compound lb-100 to enter recurrent, malignant brain tumors
Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT) announced that the National Cancer Institute (NCI) has resumed enrolling patients into their pharmacologic study of the ability of Lixte’s lead compound, LB-100, to enter the brain and penetrate recurrent, malignant brain tumors, in patients where surgical removal of their cancer is indicated. After enrolling two patients in the study, ...
-
Lixte Biotechnology’s LB-100 Reported to Convert Immunologically Unresponsive (“Cold”) Tumors to Immunologically Responsive (“Hot”) Tumors
Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, announced today that in preclinical studies its lead clinical compound, LB-100, a protein phosphatase (PP2A) inhibitor, was found to increase the responsiveness of diverse cancers to immunotherapy. In Nature Communications (15 Dec 2021), ...
-
Lixte Biotechnology announces approval of a phase 1B/2 Randomized Trial of Doxorubicin +/-LB-100 In Advanced Soft Tissue Sarcomas to Be Conducted By the Spanish Sarcoma Group
LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), (“LIXTE” or the “Company”), a clinical-stage pharmaceutical company focused on developing and commercializing cancer therapies, announced that the Spanish Agency for Medicines and Health Products (Agencia Española de Medicamentos y Productos Sanitarios, AEMPS) has authorized a Phase 1b/randomized Phase 2 study of ...
-
Inactivating Mutations in Scaffold Component of PP2A, the Target Enzyme of LIXTE Biotechnology’s Clinical Compound LB-100, are Associated with Exceptionally Long Survival of Patients with Ovarian Clear Cell Cancer Treated with Immunotherapy
LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), notes findings by a team of physician-scientists led by principal investigator Dr. Amir Jazaeri, professor of Gynecologic Oncology and Reproductive Medicine at The University of Texas MD Anderson Cancer Center, and reported at the annual meeting of Society of Gynecologic Oncology (SGO) in Phoenix, AZ, that a subset of patients with ovarian clear ...
-
FRONTBIO Inc Presented at Pharmaceutical Science 2021 anti cancer mechanism
FRONTBIO Inc. Presented at Pharmaceutical Science 2021 Disclosure of ‘Cancer cell-specific active oxygen amplification mechanism complex anticancer drug’ Mechanism, etc. FRONTBIO, a new drug development bio company, announced on October 15th that CEO Lee Jae-Yong had been invited as a speaker to the 5th International Pharmaceutical and Advanced Drug Delivery System 2021 of AAC for ...
By Frontbio
-
Mariola Fotin-Mleczek, PhD, has joined Ardigen’s Scientific Board to support the drug discovery process for cancer immunology therapies
Ardigen, one of the world’s leading companies that utilizes artificial intelligence (AI) algorithms for drug discovery, is proud to announce that Mariola Fotin-Mleczek, PhD, has joined Ardigen’s Scientific Board. Her knowledge and experience will support a deeper understanding of active cancer immunotherapies in the drug discovery process provided by scientific innovation. Mariola ...
By Ardigen
-
New phase of breast cancer treatment trial provides fresh hope for patients with incurable disease
Patients with incurable breast cancer could potentially benefit from new Welsh-led research, latest evidence suggests. The research, carried out by Velindre University NHS Trust, in partnership with AstraZeneca and Cardiff University over 10 years was presented at the world renowned American Society of Clinical Oncology conference on 4 June in Chicago and published simultaneously in the ...
By MediWales
-
ELIAS Animal Health Announces Positive Results in Treatment of Osteosarcoma in Dogs
ELIAS Animal Health, a clinical stage development company advancing novel treatments for cancer in companion animals, announced results from its canine osteosarcoma immunotherapy trial at the 2018 Veterinary Cancer Society (VCS) Annual Conference. The study evaluating ELIAS’ Autologous Prescription Product, known as ECI® (ELIAS Cancer Immunotherapy) resulted in a median survival time ...
-
NIH investigators find link between DNA damage and immune response
Researchers offer the first evidence that DNA damage can lead to the regulation of inflammatory responses, the body's reaction to injury. The proteins involved in the regulation help protect the body from infection. The study, performed by scientists at the National Institute of Environmental Health Sciences (NIEHS), which is part of the National Institutes of Health, is one of the first studies ...
-
LAVA Therapeutics Announces Treatment of First Patient in Phase 1/2a Clinical Trial of LAVA-1207 for Metastatic Castration-Resistant Prostate Cancer
LAVA’s Lead Solid Tumor Program and Second Gammabody™ T cell Engager Enters the Clinic UTRECHT, The Netherlands and PHILADELPHIA, Feb. 01, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), an immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers (bsTCEs) to transform the treatment of cancer, ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you